Furthermore, the low levels of soluble SEMA4A in MM patients are unlikely to interfere with antibody-based therapies, as soluble SEMA4A is not expected to significantly compete with a membrane-bound form for antibody binding [11]. The gene discussed is SEMA4A; the disease is Miyoshi myopathy.